US Patent Issued to AstraZeneca on June 30 for "Combination treatment by administering a recombinant apyrase protein in conjunction with a P2Y 12 inhibitor" (Swedish, Spanish Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,668,785, issued on June 30, was assigned to AstraZeneca AB (Sodertalje, Sweden).

"Combination treatment by administering a recombinant apyrase protein in conjunction with a P2Y 12 inhibitor" was invented by Leif Carlsson (Sodertalje, Sweden), Sven Nylander (Sodertalje, Sweden), Ola Fjellstrom (Sodertalje, Sweden) and Lina Badimon Maestro (Barcelona, Spain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to methods for treating ischemic events in a patient, especially ST-segment elevation myocardial infarction and acute ischemic stroke, by administrating a recombinant apyrase protein in conjunction with a P2Y12 inhibitor."

Th...